No Data
No Data
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Fly 28% But Investors Aren't Buying For Growth
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $7.5
Buy Rating Reaffirmed for Akebia Therapeutics Ahead of Vafseo's Market Launch
Express News | Akebia Therapeutics and U.S. Renal Care Initiate the Voice Trial of Vafseo® (Vadadustat) for Patients on Dialysis
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo (Vadadustat) for Patients on Dialysis
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
No Data
No Data
72138950 : Short it